NervGen Pharma Corp.

Recent News

  • NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio

    Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Dr. Jerry Silver of Case Western Reserve University ("CWRU") in...

    2020-06-22 8:15 AM ET
  • NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 225,000 incentive stock options to Directors,...

    2020-06-03 4:30 PM ET
  • NervGen Pharma Reports First Quarter 2020 Results

    Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the first quarter ended March 31, 2020.Paul...

    2020-06-01 4:43 PM ET
  • NervGen Pharma Corp. Closes Non-Brokered Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - May 20, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce that it has closed a non-brokered private placement of...

    2020-05-20 4:13 PM ET
  • NervGen Pharma Reports 2019 Year End Results

    Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) -  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2019.Paul Brennan,...

    2020-04-29 5:47 PM ET
  • NervGen Pharma Provides a Corporate Update in Response to the COVID-19 Pandemic; Announces Upcoming Presentation at Solebury Trout Virtual Investor Conference on April 7th

    Vancouver, British Columbia--(Newsfile Corp. - April 6, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided an update on its business in response to the COVID-19 global...

    2020-04-06 5:15 PM ET
  • NervGen Pharma Provides a Development Update on Its Lead Product NVG-291

    Vancouver, British Columbia--(Newsfile Corp. - February 26, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today is providing an update to its development plan for its lead program, NVG-291. These...

    2020-02-26 7:00 PM ET
  • NervGen Pharma Appoints Bill Adams as Chief Financial Officer

    Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. William (Bill) Adams, CPA, CA, to the position of...

    2020-02-24 9:00 AM ET